Cartesian Therapeutics (NASDAQ: RNAC)
NASDAQ: RNACWatertown, US · Delaware corporation · 5 known investors
Cartesian Therapeutics is a clinical-stage biotechnology company developing mRNA-based cell therapies aimed at treating autoimmune diseases. It focuses on immunology and applies an mRNA platform to broaden the use of cell therapy for patients.
Founders & leadership
MK
Metin KurtogluFounder
CJ
Chris JewellExecutive
CB
Carsten BrunninPresident and CEO
EE
Emily EnglishExecutive
BD
Blaine DavisExecutive
SS
Stephen SmolinksiExecutive
LJ
Lloyd JohnstonExecutive
BD
Bradford D. DahmsExecutive
TK
Takashi Kei KishimotoExecutive
WC
Werner CautreelsNamed on SEC filing
DS
David SiewersNamed on SEC filing
DA
David AbrahamNamed on SEC filing
Investors · 5
Reported raises · per SEC filings
Form D private placements$405.1M disclosed across 12 rounds · 2014–2024
▶$130MraisedJul 2024 · 22 investors · BiotechnologyRule 506(b)
▶$130MraisedJul 2024 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Chris JewellExecutive Officer
- Michael SingerDirector
- Kemal MalikDirector
- Carsten BrunnExecutive Officer, Director
- Metin KurtogluExecutive Officer
- Timothy C. BarabeDirector
- Timothy A. SpringerDirector
- Nishan de SilvaDirector
- Patrick ZennerDirector
- Emily EnglishExecutive Officer
- Carrie S. CoxDirector
- Blaine DavisExecutive Officer
- Murat KalayogluDirector
- Milos MiljkovicExecutive Officer
- Offering amount
- $130M
- Amount sold
- $130M
- Sales commissions
- $5M
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$60.3MraisedDec 2023 · 2 investors · BiotechnologyRule 506(b)
▶$60.3MraisedDec 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Timothy SpringerDirector
- Metin KurtogluExecutive Officer
- Aymeric SallinDirector
- Milos MiljkovicExecutive Officer
- Blaine DavisExecutive Officer
- Timothy BarabeDirector
- Murat KalayogluDirector
- Patrick ZennerDirector
- Michael SingerDirector
- Nishan De SilvaDirector
- Carsten BrunnExecutive Officer, Director
- Carrie S. CoxDirector
- Chris JewellExecutive Officer
- Offering amount
- $60.3M
- Amount sold
- $60.3M
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$25MraisedAug 2020 · 1 investors · BiotechnologyRule 506(b)
▶$25MraisedAug 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stephen SmolinksiExecutive Officer
- Lloyd JohnstonExecutive Officer
- Carrie CoxDirector
- Timothy SpringerDirector
- Scott MyersDirector
- Timothy BarabeDirector
- Bradford D. DahmsExecutive Officer
- Carsten BrunnExecutive Officer, Director
- Takashi Kei KishimotoExecutive Officer
- Goran AndoDirector
- Patrick ZennerDirector
- Aymeric SallinDirector
- Elona KoganExecutive Officer
- Offering amount
- $25M
- Amount sold
- $25M
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$70MraisedJan 2020 · 26 investors · BiotechnologyRule 506(b)
▶$70MraisedJan 2020 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Elona KoganExecutive Officer
- Stephen SmolinskiExecutive Officer
- Amir NashatDirector
- Scott Dunseth MyersDirector
- Aymeric SallinDirector
- Timothy SpringerDirector
- Patrick ZennerDirector
- Alison SchecterExecutive Officer
- Timothy BarabeDirector
- Carsten BrunnExecutive Officer, Director
- Bradford DahmsExecutive Officer
- Lloyd JohnstonExecutive Officer
- Takashi Kei KishimotoExecutive Officer
- Carrie CoxDirector
- Offering amount
- $70M
- Amount sold
- $70M
- Sales commissions
- $4.2M
- Placement agents
- Cantor Fitzgerald LP, Janney Montgomery Scott LLC, Canaccord Genuity LLC, Needham & Company
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.8MraisedSep 2019 · 10 investors · BiotechnologyRule 506(b)
▶$5.8MraisedSep 2019 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patrick ZennerDirector
- Timothy SpringerDirector
- Aymeric SallinDirector
- Amir NashatDirector
- Timothy BarabeDirector
- Omid FarokhzadDirector
- Alison SchecterExecutive Officer
- Stephen SmolinskiExecutive Officer
- Elona KoganExecutive Officer
- Scott D. MyersDirector
- Carsten BrunnExecutive Officer, Director
- Lloyd JohnstonExecutive Officer
- Takashi Kei KishimotoExecutive Officer
- Offering amount
- $5.8M
- Amount sold
- $5.8M
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$50MraisedJul 2017 · 11 investors · BiotechnologyRule 506(b)
▶$50MraisedJul 2017 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David AbrahamExecutive Officer
- Werner CautreelsExecutive Officer, Director
- Earl SandsExecutive Officer
- Omid FarokhzadDirector
- Patrick ZennerDirector
- Aymeric SallinDirector
- Timothy SpringerDirector
- Timothy C. BarabeDirector
- Peter KellerExecutive Officer
- Takashi Kei KishimotoExecutive Officer
- David SiewersExecutive Officer
- Lloyd JohnstonExecutive Officer
- Amir NashatDirector
- Peter Barton HuttDirector
- Offering amount
- $50M
- Amount sold
- $50M
- Sales commissions
- $2.6M
- Placement agents
- Stifel, Nicolaus & Company Incorporated
- First sale
- Jun 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedDec 2016 · 1 investors · BiotechnologyRule 506(b)
▶$5MraisedDec 2016 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter Barton HuttDirector
- Takashi Kei KishimotoExecutive Officer
- Amir NashatDirector
- Aymeric SallinDirector
- Carl GordonDirector
- Omid FarokhzadDirector
- Lloyd JohnstonExecutive Officer
- Edwin M. Kania, Jr.Director
- Timothy C. BarabeDirector
- David SiewersExecutive Officer
- Peter KellerExecutive Officer
- Earl SandsExecutive Officer
- Timothy SpringerDirector
- Werner CautreelsExecutive Officer, Director
- David AbrahamExecutive Officer
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$37.4MraisedSep 2015 · 19 investors · BiotechnologyRule 506(b)
▶$37.4MraisedSep 2015 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Takashi Kei KishimotoExecutive Officer
- Aymeric SallinDirector
- Lloyd JohnstonExecutive Officer
- Amir NashatDirector
- Omid FarokhzadDirector
- Robert LangerDirector
- Leysan ShaydullinaDirector
- David AbrahamExecutive Officer
- Peter KellerExecutive Officer
- David SiewersExecutive Officer
- Earl SandsExecutive Officer
- Werner CautreelsExecutive Officer, Director
- Edwin M. Kania, Jr.Director
- Carl GordonDirector
- George SiberDirector
- Peter Barton HuttDirector
- Offering amount
- $40.6M
- Amount sold
- $37.4M
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapKite Pharma62 shared keywordsKite Pharma develops CAR T-cell therapies for cancer patients, engineering the immune system's cells to target and attack cancer. Each therapy is individualized per patient through a multi-step manufacturing process.
Dialectic Therapeutics41 shared keywordsDialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.
Solu33 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Companies competing with Cartesian Therapeutics (NASDAQ: RNAC) for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $299K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Cartesian Therapeutics (NASDAQ: RNAC) do?
- Cartesian Therapeutics is a clinical-stage biotechnology company developing mRNA-based cell therapies aimed at treating autoimmune diseases. It focuses on immunology and applies an mRNA platform to broaden the use of cell therapy for patients.
- Who founded Cartesian Therapeutics (NASDAQ: RNAC)?
- Cartesian Therapeutics (NASDAQ: RNAC) was founded by Metin Kurtoglu.
- Who are Cartesian Therapeutics (NASDAQ: RNAC)'s investors?
- Cartesian Therapeutics (NASDAQ: RNAC)'s investors include K2 HealthVentures, Maryland TEDCO, Schooner Capital, TEDCO, Polaris Partners.
- How much funding has Cartesian Therapeutics (NASDAQ: RNAC) raised?
- Cartesian Therapeutics (NASDAQ: RNAC) has disclosed $405.1M raised across 12 rounds.
- Where is Cartesian Therapeutics (NASDAQ: RNAC) headquartered?
- Cartesian Therapeutics (NASDAQ: RNAC) is headquartered in Watertown, US.